Clinical trial
Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A…
NCT00255008 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00255008 |
|---|---|
| Title | Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212) |
| Official title | SEASON South East Asian Study Of Novel Genotypes in Hepatitis C Infection: Pegylated-Interferon and Ribavirin Therapy (PEGATRON REDIPEN Combination Therapy (PEG-Intron® REDIPEN Plus REBETOL®)) in Treatment Naive Patients With Genotypes 1, 6, 7, 8, 9: A Comparison of Race and Genotype on Treatment… |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Biological, Drug |
| Interventions | peginterferon alfa-2b, ribavirin |
| Enrollment | 121 |
| Start date | Mar 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Nov 17, 2005 |
| Last update posted | Apr 6, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: